Overview
Pro Medicus Limited is an Australian-based company specializing in radiology information systems (RIS), picture archiving and communication systems (PACS), and other advanced medical imaging software. Founded in 1983, the company has evolved to become a prominent provider in the healthcare sector, notably in medical imaging and diagnostics technologies. Pro Medicus leverages its Visage 7 platform to deliver high-performance, scalable imaging solutions that support server-side processing and streamline diagnostic workflows across various medical settings. This technology has facilitated substantial advancements in reading efficiency and diagnostic accuracy in the health sector. The company has successfully expanded its footprint by securing multiple high-value contracts with leading hospital networks in North America, Europe, and Australia, enhancing its market presence and reinforcing its expertise in healthcare imaging solutions.
AI+ Ask Fintel’s AI assistant about Pro Medicus Limited - Depositary Receipt (Common Stock).
Thinking about good questions…
Basic Stats
The share price of Pro Medicus Limited - Depositary Receipt (Common Stock) as of April 16, 2024 is $13.25 / share.
The Factor Analysis chart (below right) shows a view of Pro Medicus Limited - Depositary Receipt (Common Stock) from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 104.46 MM |
| Earnings Date | |
| EPS (TTM) | 1.10 |
| Dividend Yield | |
| Ex-Dividend Date | 2025-09-04 |
| Borrow Rate | 10.51 |
| Short Shares Avail. | 0.00 MM |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.45 |
| ROE | 0.61 |
| ROIC | 0.44 |
| CROIC | 0.18 |
| OCROIC | 0.43 |
| Implied Volatility | |
| Put/Call OI Ratio |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Pro Medicus Limited - Depositary Receipt (Common Stock) is $47.09. The forecasts range from a low of -$16.88 to a high of $70.18. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Pro Medicus Limited - Depositary Receipt (Common Stock). An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-12-19 | BELL POTTER SECURITIES | Hold | Hold | Maintains |
| 2023-10-25 | MOELIS AUSTRALIA SECURITIES | Hold | Hold | Maintains |
| 2023-09-26 | WILSONS | Overweight | Overweight | Maintains |
| 2023-08-31 | BELL POTTER SECURITIES | Hold | Hold | Maintains |
| 2023-08-30 | BELL POTTER SECURITIES | Hold | Hold | Maintains |
| 2023-08-30 | WILSONS | Overweight | Overweight | Maintains |
| 2023-08-29 | WILSONS | Overweight | Overweight | Maintains |
| 2023-08-16 | MOELIS AUSTRALIA SECURITIES | Hold | Hold | Maintains |
| 2023-08-15 | MOELIS AUSTRALIA SECURITIES | Hold | Hold | Maintains |
| 2023-05-16 | MOELIS AUSTRALIA SECURITIES | Hold | Hold | Maintains |
| 2023-05-15 | MOELIS AUSTRALIA SECURITIES | Hold | Hold | Maintains |
| 2023-03-23 | BELL POTTER SECURITIES | Sell | Hold | Upgrade |
| 2023-03-22 | BELL POTTER SECURITIES | Sell | Hold | Upgrade |
| 2023-02-21 | BELL POTTER SECURITIES | Hold | Sell | Downgrade |
| 2023-02-20 | BELL POTTER SECURITIES | Hold | Sell | Downgrade |
| 2023-02-16 | MOELIS AUSTRALIA SECURITIES | Hold | Hold | Maintains |
| 2023-02-15 | WILSONS | Overweight | Overweight | Maintains |
| 2023-02-14 | WILSONS | Overweight | Overweight | Maintains |
| 2022-09-01 | BELL POTTER SECURITIES | Buy | Hold | Downgrade |
| 2022-08-31 | BELL POTTER SECURITIES | Buy | Hold | Downgrade |
| 2022-06-03 | BELL POTTER SECURITIES | Hold | Buy | Upgrade |
| 2022-06-02 | BELL POTTER SECURITIES | Hold | Buy | Upgrade |
| 2021-09-30 | BELL POTTER SECURITIES | Hold | Hold | Maintains |
| 2021-09-29 | BELL POTTER SECURITIES | Hold | Hold | Maintains |
| 2021-02-18 | MOELIS AUSTRALIA SECURITIES | Hold | Hold | Maintains |
| 2021-02-17 | MOELIS AUSTRALIA SECURITIES | Hold | Hold | Maintains |
| 2024-07-03 | BELL POTTER SECURITIES | Hold | Hold | Maintains |
| 2024-07-01 | MACQUARIE RESEARCH | Outperform | Outperform | Maintains |
| 2024-02-15 | MOELIS AUSTRALIA SECURITIES | Hold | Hold | Maintains |
| 2024-01-29 | BELL POTTER SECURITIES | Hold | Hold | Maintains |
| 2023-12-18 | BELL POTTER SECURITIES | Hold | Hold | Maintains |
| 2023-10-24 | MOELIS AUSTRALIA SECURITIES | Hold | Hold | Maintains |
| 2023-09-25 | WILSONS | Overweight | Overweight | Maintains |
| 2025-04-07 | BELL POTTER SECURITIES | Buy | Hold | Downgrade |
| 2025-03-30 | MACQUARIE RESEARCH | Neutral | Neutral | Maintains |
| 2025-03-26 | BELL POTTER SECURITIES | Hold | Buy | Upgrade |
| 2025-03-25 | JEFFERIES | Hold | Hold | Maintains |
| 2025-03-22 | E&P | Neutral | Neutral | Maintains |
| 2025-02-13 | MOELIS AUSTRALIA SECURITIES | Hold | Hold | Maintains |
| 2025-02-12 | WILSONS | Overweight | Overweight | Maintains |
| 2025-01-06 | WILSONS | Overweight | Overweight | Maintains |
| 2024-12-04 | BELL POTTER SECURITIES | Hold | Hold | Maintains |
| 2024-11-28 | E&P | Neutral | Neutral | Maintains |
| 2024-11-18 | MACQUARIE RESEARCH | Outperform | Neutral | Downgrade |
| 2024-10-28 | MACQUARIE RESEARCH | Outperform | Outperform | Maintains |
| 2024-08-14 | MOELIS AUSTRALIA SECURITIES | Hold | Hold | Maintains |
| 2025-07-16 | MACQUARIE RESEARCH | Neutral | Neutral | Maintains |
| 2025-07-14 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2025-07-03 | MOELIS AUSTRALIA SECURITIES | Hold | Hold | Maintains |
| 2025-07-02 | JEFFERIES | Hold | Hold | Maintains |
| 2025-07-02 | E&P | Neutral | Neutral | Maintains |
| 2025-07-02 | BELL POTTER SECURITIES | Hold | Buy | Upgrade |
